文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas.

作者信息

Sievers Philipp, Hielscher Thomas, Schrimpf Daniel, Stichel Damian, Reuss David E, Berghoff Anna S, Neidert Marian C, Wirsching Hans-Georg, Mawrin Christian, Ketter Ralf, Paulus Werner, Reifenberger Guido, Lamszus Katrin, Westphal Manfred, Etminan Nima, Ratliff Miriam, Herold-Mende Christel, Pfister Stefan M, Jones David T W, Weller Michael, Harter Patrick N, Wick Wolfgang, Preusser Matthias, von Deimling Andreas, Sahm Felix

机构信息

Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Clinical Cooperation Unit Neuropathology (B300), German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.

出版信息

Acta Neuropathol. 2020 Sep;140(3):409-413. doi: 10.1007/s00401-020-02188-w. Epub 2020 Jul 8.

DOI:10.1007/s00401-020-02188-w
PMID:32642869
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7423850/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69fd/7423850/5d5fc90f9c4f/401_2020_2188_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69fd/7423850/5d5fc90f9c4f/401_2020_2188_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69fd/7423850/5d5fc90f9c4f/401_2020_2188_Fig1_HTML.jpg

相似文献

[1]
CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas.

Acta Neuropathol. 2020-9

[2]
Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas.

Acta Neuropathol. 2023-4

[3]
Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas.

Acta Neuropathol. 2023-7

[4]
p16 Immunohistochemistry as a Screening Tool for Homozygous CDKN2A Deletions in CNS Tumors.

Am J Surg Pathol. 2024-1-1

[5]
[Methylthioadenosine phosphorylase and p16 as surrogate diagnostic markers for CDKN2A homozygous deletion in brain tumors].

Zhonghua Bing Li Xue Za Zhi. 2024-5-8

[6]
Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.

Am J Pathol. 2001-8

[7]
Correlation of MTAP Immunohistochemistry With CDKN2A Status Assessed by Fluorescence In Situ Hybridization and Clinicopathological Features in CNS WHO Grade 2 and 3 Meningiomas: A Single Center Cohort Study.

J Neuropathol Exp Neurol. 2022-1-29

[8]
Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma.

J Neurooncol. 2019-11-15

[9]
Even heterozygous loss of CDKN2A/B greatly accelerates recurrence in aggressive meningioma.

Acta Neuropathol. 2023-4

[10]
CDKN2A/B deletions are strongly associated with meningioma progression: a meta-analysis of individual patient data.

Acta Neuropathol Commun. 2023-11-28

引用本文的文献

[1]
Spatially Encoded Oncogenesis and Transcriptional Plasticity in Meningioma: Drivers of Therapeutic Resistance and Opportunities for Targeted Intervention.

Cancers (Basel). 2025-8-19

[2]
Targeting epigenetic modifications as an emerging immunotherapeutic strategy for cancers.

Immunol Res. 2025-8-19

[3]
The concept, intention, and evaluation of the term treatment-refractory meningioma.

J Neurooncol. 2025-11

[4]
EZH2 overexpression is associated with aggressive behavior and promotes cell proliferation in CNS WHO grade 3 meningiomas.

Neurooncol Adv. 2025-6-5

[5]
Pan-cancer copy number analysis identifies optimized size thresholds and co-occurrence models for individualized risk stratification.

Nat Commun. 2025-7-2

[6]
Case Report: The price of intraoperative cell salvage? - implantation metastases of meningioma in both lungs and left cubital fossa.

Front Oncol. 2025-5-28

[7]
Radiation-Induced Meningiomas Have an Aggressive Clinical Course: Genetic Signature Is Limited to Alterations, and Epigenetic Signature Is H3K27me3 Loss.

J Korean Med Sci. 2025-5-12

[8]
Prognostic value of MIB-1 index in meningioma: a retrospective cohort study to establish an optimal cutoff for recurrence and survival.

J Neurooncol. 2025-5-12

[9]
Comprehensive analysis of prognosis and tumor immune microenvironment of cuproptosis-related gene CDKN2A in lung adenocarcinoma.

BMC Pulm Med. 2025-4-14

[10]
Meningioma: Novel Diagnostic and Therapeutic Approaches.

Biomedicines. 2025-3-7

本文引用的文献

[1]
Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis.

J Neurol Neurosurg Psychiatry. 2020-2-10

[2]
Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma.

J Neurooncol. 2019-11-15

[3]
DNA methylation-based classification of central nervous system tumours.

Nature. 2018-3-14

[4]
DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.

Lancet Oncol. 2017-3-15

[5]
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Acta Neuropathol. 2016-5-9

[6]
Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets.

Acta Neuropathol. 2015-12-15

[7]
TERT Promoter Mutations and Risk of Recurrence in Meningioma.

J Natl Cancer Inst. 2015-12-13

[8]
Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.

Acta Neuropathol. 2013-10-24

[9]
Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status.

Clin Cancer Res. 2010-8-3

[10]
New classification scheme for the prognostic stratification of meningioma on the basis of chromosome 14 abnormalities, patient age, and tumor histopathology.

J Clin Oncol. 2003-9-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索